Privacy

Cookie Policy

Contact

Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeEXECUTIVESActiv Surgical New Appointments

Activ Surgical New Appointments

Richard Stamm as Vice President, General Counsel and Mark Johnson as Vice President, Global Sales

Richard Stamm has been appointed vice president, general counsel, and Mark Johnson as vice president, global sales. In his role as general counsel, Stamm will oversee all aspects of Activ Surgical’s legal and corporate governance matters, while Johnson will spearhead the company’s sales organization.

These key executive appointments are being made between two significant company milestones–a $45 million Series B fundraise, announced in September 2021, and commercialization of its ActivInsights™ software suite, which is targeted for early 2022.

Richard Stamm brings 30 years of corporate and securities law experience to Activ Surgical. He started his career with leading law firm Dechert, LLP., before moving in-house at Ocean Spray Cranberries, Inc. where, as general counsel, he provided strategic guidance on the full range of legal issues faced by a global branded company. Following Ocean Spray, Stamm joined Agrify Corporation as its general counsel, helping to navigate the company through the legal complexities in preparing for its initial public offering (IPO). Most recently, he maintained his own legal and consulting firm, leveraging his practical business law and corporate governance expertise to advise a variety of businesses and their leaders. Stamm has a degree in business economics from Brown University and received his law degree from the University of Connecticut School of Law.

“I am excited to join Activ Surgical at a critical inflection point in the company’s history,” said Stamm. “With the impending commercial launch of its ActivInsight software suite, there is an abundance of interrelated commercial, business and regulatory activities to manage. I look forward to working with the Activ Surgical leadership team and the entire organization to guide them through these complexities.”

Johnson is a proven sales leader and executive with 20+ years of experience, and comes to Activ Surgical from Hologic, Inc., where he led the U.S. Commercial Skeletal business, as well as Western U.S. Breast and Skeletal Health team with collective sales and service revenue responsibility of $400M+. Across his leadership roles, he has excelled in his responsibilities of driving sales transformation, increasing revenue and profitability growth, attracting and selecting top talent, employee development, sales targeting and optimization, cross-functional leadership, culture development, and key account management. Previous to his time at Hologic, Johnson held leadership positions at Stryker, Smith & Nephew, and Elekta. He has a degree in biology from The University of Georgia.

“With preventable surgical errors costing our global healthcare system approximately $36 billion dollars, Activ Surgical and its innovative technology platform have a massive opportunity to usher in a new era of patient care and safety in the operating room,” said Johnson. “I plan to embrace the growth opportunities ahead as the company moves toward commercialization and am confident we will fulfill our mission to democratize surgical care around the globe.”

“Activ Surgical is growing rapidly after our Series B fundraise in September of this year, and Rich and Mark will both play critical roles in continuing this upward trajectory and ensuring success for the commercial launch of our first product–the ActivInsights software suite–in 2022,” said Todd, Usen, chief executive officer, Activ Surgical. “Both executives bring an outstanding track record in their respective fields, and I am thrilled to have them join our leadership team.”

spot_img

DON'T MISS

United States Cardiovascular Devices Market 2021-2027

United States Cardiovascular Devices Market is projected to reach US$ 39.98 Billion by 2027 from US$ 25.34 Billion in 2020, growing with a CAGR of 6.73%

Global Cerebrospinal Fluid Drainage Catheter Market (2021 to 2027) – by Application, Type and Regional Outlook

The Global Cerebrospinal Fluid Drainage Catheter Market size is expected to reach $402.6 Million by 2027, rising at a market growth of 8.6% CAGR during the forecast period. For the treatment of hydrocephalus, placement of cerebral spinal fluid (CSF) shunt systems is becoming a common medical and life-saving procedure for the majority of the patients.

United States Insulin Delivery Devices Market Report 2021

This new report provides an in-depth assessment of the U.S insulin delivery devices market dynamics, opportunities, future road-map, competitive landscape and discusses major trends.

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy